Literature DB >> 15091211

Factors predictive of local disease control after intra-arterial concomitant chemoradiation (RADPLAT).

K Thomas Robbins1, Ilana Doweck, Sandeep Samant, Francisco Vieira, Parvesh Kumar.   

Abstract

OBJECTIVES: To determine the relative risk of prognostic factors for local disease control following RADPLAT. STUDY
DESIGN: Prospective study, academic medical center.
METHODS: Analyses of nine categories of risk factors among 240 patients with Stage II-IV carcinoma consecutively treated with RADPLAT (cisplatin 150 mg/m IA and sodium thiosulfate 9 g/m IV, weekly x4; radiotherapy 2 Gy/fraction/d, 5x weekly, 68-74 Gy over 6 to 7 weeks). Median follow-up: 58 months (range, 12-96 mo).
RESULTS: The percentage of patients who had local disease control was 87.5%. Univariant analysis showed T classification (P =.01), laterality of neck disease (P =.026), number of neck levels involved (P =.008), total dose of radiation greater versus less than 60 Gy (P =.027), and presence of pathologically positive lymph nodes following chemoradiation (P =.01) to be significant. Logistic regression analysis showed total dose of radiation (P =.03) and the presence of pathologically positive lymph nodes following chemoradiation (P =.05) to be significant. For Kaplan-Meier estimates of local disease control at 5 years, T classification (P =.038), number of levels with nodal disease (P =.006), and total dose of radiation therapy (P =.0001) were significant. The log-rank test identified as significant the total dose of radiation therapy (P <.0001), the presence of pathologically positive lymph nodes following chemoradiation (P =.005), and the number of neck levels with positive nodes (P =.006). The Cox regression model showed significance for the total dose of radiation (P =.001), the presence of pathologically positive lymph nodes following chemoradiation (P =.007), and the T classification (P =.029).
CONCLUSION: Risk factors significantly associated with local disease control after RADPLAT appears to differ from more traditional therapy and is suggestive of a paradigm shift.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15091211     DOI: 10.1097/00005537-200403000-00004

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  4 in total

1.  Blood vessel density correlates with the effects of targeted intra-arterial carboplatin infusion with concurrent radiotherapy for squamous cell carcinomas of the oral cavity and oropharynx.

Authors:  S Takagi; R Inenaga; R Oya; S Nakamura; K Ikemura
Journal:  Br J Cancer       Date:  2006-06-05       Impact factor: 7.640

2.  Concurrent intra-arterial carboplatin administration and radiation therapy for the treatment of advanced head and neck squamous cell carcinoma: short term results.

Authors:  Giulia Bertino; Antonio Occhini; Carlo Emilio Falco; Camillo Porta; Franco Corbella; Sara Colombo; Vittoria Balcet; Patrizia Morbini; Federico Zappoli; Andrea Azzaretti; Giuseppe Rodolico; Carmine Tinelli; Marco Benazzo
Journal:  BMC Cancer       Date:  2009-09-04       Impact factor: 4.430

3.  Intra-arterial chemoradiation for T3-4 oral cavity cancer: treatment outcomes in comparison to oropharyngeal and hypopharyngeal carcinoma.

Authors:  Ilana Doweck; K Thomas Robbins; Sandeep Samant; Francisco Vieira
Journal:  World J Surg Oncol       Date:  2008-01-14       Impact factor: 2.754

4.  Daily Cisplatin and Weekly Docetaxel versus Weekly Cisplatin Intra-Arterial Chemoradiotherapy for Late T2-3 Tongue Cancer: A Pilot and Feasibility Trial.

Authors:  Yuichiro Hayashi; Shuhei Minamiyama; Takashi Ohya; Masaki Iida; Toshinori Iwai; Toshiyuki Koizumi; Senri Oguri; Makoto Hirota; Mitomu Kioi; Masaharu Hata; Masataka Taguri; Kenji Mitsudo
Journal:  Medicina (Kaunas)       Date:  2018-07-30       Impact factor: 2.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.